Drug intelligence / Profile preview

sevoflurane + nitrous oxide

Development stage
Phase 4
Lead developer
AbbVie
Modality
Small Molecules
Administration
Inhalation
01

Overview

Sevoflurane + nitrous oxide is a combination of two inhaled anesthetic agents commonly used for the induction and maintenance of general anesthesia in both adult and pediatric patients. Sevoflurane is a volatile halogenated ether anesthetic that acts primarily by enhancing inhibitory neurotransmission (notably via GABA(A) and glycine receptors) and inhibiting excitatory synaptic activity (including antagonism at glutamate receptors). Nitrous oxide, also known as "laughing gas," is an inhaled anesthetic with analgesic properties that works mainly as an NMDA receptor antagonist. When used together, these agents provide rapid onset anesthesia with muscle relaxation, amnesia, hypnosis, and analgesia. The combination is widely employed in surgical settings due to its favorable pharmacokinetic profile—sevoflurane offers fast induction/emergence while nitrous oxide augments the depth of anesthesia and reduces the required dose of sevoflurane[1][2][3][4][5][6][8].

Other names
laughing gas
02

Targets

GABRR (GABA-A receptor subunit rho)GRIA1 (AMPA receptor subunit GluA1)GLRA1 (Glycine receptor subunit Alpha-1)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on sevoflurane + nitrous oxide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sevoflurane + nitrous oxide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call